Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.
about
Venous thromboembolism and cancer risk among elderly adults in the United States.Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma.The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.Pulmonary embolism as the first manifestation of multiple myeloma.Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.Thromboembolic risk in hematological malignancies.Biomarkers for Prediction of Central Venous Catheter Related-Thrombosis in Patients With Hematological Malignancies.Nonsecretory multiple myeloma presenting as an intestinal tumor.Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers.Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia.Hemostatic Abnormalities in Multiple Myeloma PatientsLaboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review.Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.Is coagulation factor VIII a useful marker for colorectal carcinoma?
P2860
Q33608869-4371639D-8F22-4021-84C4-003A7E0275FAQ36420952-1BAC898A-8F71-4883-A7E0-A32D5E3CDA6FQ36612613-1C125099-A5AE-48CA-86F1-E07E388C693DQ36697556-1716B3DA-F499-428D-B2DB-B281EBF0CC39Q36948554-146D6891-FD7E-4D67-9B17-125523842F99Q37038414-718AB8A1-5011-4ED0-B059-E0F6E4759925Q37212264-DB37AC50-98A1-4CD6-8514-A630DDE698ABQ38230423-11F49EEF-2EEC-4401-8419-CF4650055E16Q38287304-7384A916-3114-495C-83A6-2F6A709C11F2Q39016660-BA8D79FD-E1B6-42FB-A3F6-DEC6E59FA8C5Q40119005-B9C55789-D215-4DAA-8548-63FE1990BD6FQ44281692-A4274FAC-2063-4E70-BBD0-20D343791847Q46872004-7E53840B-D3C6-4C19-BBD0-AC745EDD3B23Q49648633-77BEB788-3140-4E81-B8D5-664D16A0AAB9Q50174496-8F47D9B4-DCF4-4B6D-B386-5977205207E9Q55617050-9F8C0F9D-71BD-42FA-9661-C674F3421F1AQ58028690-382A1E76-C9ED-43B9-A2F1-0DCA090E1396
P2860
Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Prothrombotic coagulation abno ...... ly diagnosed multiple myeloma.
@en
Prothrombotic coagulation abno ...... ly diagnosed multiple myeloma.
@nl
type
label
Prothrombotic coagulation abno ...... ly diagnosed multiple myeloma.
@en
Prothrombotic coagulation abno ...... ly diagnosed multiple myeloma.
@nl
prefLabel
Prothrombotic coagulation abno ...... ly diagnosed multiple myeloma.
@en
Prothrombotic coagulation abno ...... ly diagnosed multiple myeloma.
@nl
P2093
P356
P1433
P1476
Prothrombotic coagulation abno ...... ly diagnosed multiple myeloma.
@en
P2093
Frank W G Leebeek
Johannes J A Auwerda
Monica P M de Maat
P304
P356
10.3324/HAEMATOL.10454
P577
2007-02-01T00:00:00Z